In the MONALEESA‐2 trial of ribociclib, circulating tumor DNA (ctDNA) analysis revealed that patients with FGFR1 amplification had shorter PFS than those carrying wild‐type FGFR1. The gene discussed is FGFR1; the disease is neoplasm.